Q1 Earnings Forecast for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Analysts at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for Longeveron in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.37) per share for the quarter, up from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.31) EPS.

LGVN has been the subject of a number of other research reports. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They issued a “buy” rating and a $10.00 target price for the company. Roth Capital upgraded Longeveron to a “strong-buy” rating in a report on Thursday, December 5th.

Longeveron Stock Performance

Shares of NASDAQ:LGVN opened at $1.40 on Thursday. The stock has a fifty day moving average of $1.64 and a 200-day moving average of $1.89. The company has a market capitalization of $20.77 million, a PE ratio of -0.22 and a beta of 0.36. Longeveron has a one year low of $0.77 and a one year high of $6.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp bought a new position in Longeveron during the third quarter worth about $29,000. Geode Capital Management LLC raised its stake in shares of Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Longeveron in the fourth quarter valued at approximately $35,000. Northern Trust Corp acquired a new stake in shares of Longeveron in the fourth quarter valued at approximately $31,000. Finally, Virtu Financial LLC acquired a new stake in Longeveron during the 4th quarter worth $53,000. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.